Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance von Turner, David C, Kondic, Anna G, Anderson, Keaven M, Robinson, Andrew G, Garon, Edward B, Riess, Jonathan Wesley, Jain, Lokesh, Mayawala, Kapil, Kang, Jiannan, Ebbinghaus, Scot W, Sinha, Vikram, de Alwis, Dinesh P, Stone, Julie A

Volltext

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial von Finn, Richard S., Ryoo, Baek-Yeol, Merle, Philippe, Kudo, Masatoshi, Bouattour, Mohamed, Lim, Ho Yeong, Breder, Valeriy, Edeline, Julien, Chao, Yee, Ogasawara, Sadahisa, Yau, Thomas, Garrido, Marcelo, Chan, Stephen L., Knox, Jennifer, Daniele, Bruno, Ebbinghaus, Scot W., Chen, Erluo, Siegel, Abby B., Zhu, Andrew X., Cheng, Ann-Lii

Volltext

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial von Zhu, Andrew X, Finn, Richard S, Edeline, Julien, Cattan, Stephane, Ogasawara, Sadahisa, Palmer, Daniel, Verslype, Chris, Zagonel, Vittorina, Fartoux, Laetitia, Vogel, Arndt, Sarker, Debashis, Verset, Gontran, Chan, Stephen L, Knox, Jennifer, Daniele, Bruno, Webber, Andrea L, Ebbinghaus, Scot W, Ma, Junshui, Siegel, Abby B, Cheng, Ann-Lii, Kudo, Masatoshi, Alistar, Angela, Asselah, Jamil, Blanc, Jean-Frederic, Borbath, Ivan, Cannon, Timothy, Chung, Ki, Cohn, Allen, Cosgrove, David P, Damjanov, Nevena, Gupta, Mukul, Karino, Yoshivasu, Karwal, Mark, Kaubisch, Andreas, Kelley, Robin, Van Laethem, Jena-Luc, Larson, Timothy, Lee, James, Li, Daneng, Manhas, Atisha, Manji, Gulam Abbas, Numata, Kazushi, Parsons, Benjamin, Paulson, Andrew S., Pinto, Carmine, Ramirez, Robert, Ratnam, Suresh, Rizell, Magnus, Rosmorduc, Olivier, Sada, Yvonne, Sasaki, Yutaka, Stal, Per I, Strasser, Simone, Trojan, Joerg, Vaccaro, Gina, Van Vlierberghe, Hans, Weiss, Alan, Weiss, Karl-Heinz, Yamashita, Tatsuya

Volltext

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma von Hamid, Omid, Robert, Caroline, Daud, Adil, Hodi, F. Stephen, Hwu, Wen-Jen, Kefford, Richard, Wolchok, Jedd D, Hersey, Peter, Joseph, Richard W, Weber, Jeffrey S, Dronca, Roxana, Gangadhar, Tara C, Patnaik, Amita, Zarour, Hassane, Joshua, Anthony M, Gergich, Kevin, Elassaiss-Schaap, Jeroen, Algazi, Alain, Mateus, Christine, Boasberg, Peter, Tumeh, Paul C, Chmielowski, Bartosz, Ebbinghaus, Scot W, Li, Xiaoyun Nicole, Kang, S. Peter, Ribas, Antoni

Volltext

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial von Robert, Caroline, Prof, Ribas, Antoni, Prof, Wolchok, Jedd D, Prof, Hodi, F Stephen, MD, Hamid, Omid, MD, Kefford, Richard, Prof, Weber, Jeffrey S, Prof, Joshua, Anthony M, PhD, Hwu, Wen-Jen, Prof, Gangadhar, Tara C, MD, Patnaik, Amita, MD, Dronca, Roxana, MD, Zarour, Hassane, Prof, Joseph, Richard W, MD, Boasberg, Peter, MD, Chmielowski, Bartosz, MD, Mateus, Christine, MD, Postow, Michael A, MD, Gergich, Kevin, MA, Elassaiss-Schaap, Jeroen, PhD, Li, Xiaoyun Nicole, PhD, Iannone, Robert, MD, Ebbinghaus, Scot W, MD, Kang, S Peter, MD, Daud, Adil, Prof

Volltext

Formation of a Unique End-to-End Stacked Pair of G-Quadruplexes in the hTERT Core Promoter with Implications for Inhibition of Telomerase by G-Quadruplex-Interactive Ligands von Palumbo, SunMi L, Ebbinghaus, Scot W, Hurley, Laurence H

Volltext

Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules von ADVANI, Ranjana H, HURWITZ, Herbert I, FOX, Judith A, ALLEN, Roberta S, ADELMAN, Daniel C, GORDON, Michael S, EBBINGHAUS, Scot W, MENDELSON, David S, WAKELEE, Heather A, HOCH, Ute, SILVERMAN, Jeffrey A, HAVRILLA, Nancy A, BERMAN, Craig J

Volltext

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work Group von Harvey, R. Donald, Mileham, Kathryn F., Bhatnagar, Vishal, Brewer, Jamie R., Rahman, Atiqur, Moravek, Cassadie, Kennedy, Andrew S., Ness, Elizabeth A., Dees, E. Claire, Ivy, S. Percy, Ebbinghaus, Scot W., Schenkel, Caroline, Uldrick, Thomas S.

Volltext

Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma von Grossmann, Kenneth F, Othus, Megan, Patel, Sapna P, Tarhini, Ahmad A, Sondak, Vernon K, Knopp, Michael V, Petrella, Teresa M, Truong, Thach-Giao, Khushalani, Nikhil I, Cohen, Justine V, Buchbinder, Elizabeth I, Kendra, Kari, Funchain, Pauline, Lewis, Karl D, Conry, Robert M, Chmielowski, Bartosz, Kudchadkar, Ragini R, Johnson, Douglas B, Li, Hongli, Moon, James, Eroglu, Zeynep, Gastman, Brian, Kovacsovics-Bankowski, Magdalena, Gunturu, Krishna S, Ebbinghaus, Scot W, Ahsan, Sama, Ibrahim, Nageatte, Sharon, Elad, Korde, Larissa A, Kirkwood, John M, Ribas, Antoni

Volltext

Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices von Cowey, C Lance, Liu, Frank Xiaoqing, Black-Shinn, Jenny, Stevinson, Kendall, Boyd, Marley, Frytak, Jennifer R, Ebbinghaus, Scot W

Volltext

Evidence for the Presence of a Guanine Quadruplex Forming Region within a Polypurine Tract of the Hypoxia Inducible Factor 1α Promoter von De Armond, Richard, Wood, Stacey, Sun, Daekyu, Hurley, Laurence H, Ebbinghaus, Scot W

Volltext

novel G-quadruplex-forming GGA repeat region in the c-myb promoter is a critical regulator of promoter activity von Palumbo, SunMi L, Memmott, Regan M, Uribe, Diana J, Krotova-Khan, Yulia, Hurley, Laurence H, Ebbinghaus, Scot W

Volltext

Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC) von Meulenbeld, Hielke J., de Bono, Johann S., Tagawa, Scott T., Whang, Young E., Li, Xiaoyun, Heath, Karl H., Zandvliet, Anthe S., Ebbinghaus, Scot W., Hudes, Gary R., de Wit, Ronald

Volltext

PNA−Nitrogen Mustard Conjugates Are Effective Suppressors of HER-2/neu and Biological Tools for Recognition of PNA/DNA Interactions von Zhilina, Zhanna V, Ziemba, Amy J, Nielsen, Peter E, Ebbinghaus, Scot W

Volltext

Mechanism of PNA Transport to the Nuclear Compartment von STANKOVA, LENKA, ZIEMBA, AMY J., ZHILINA, ZHANNA V., EBBINGHAUS, SCOT W.

Volltext

Abstract CN02-02: Dual inhibition of mTOR and IGFR pathways von Ebbinghaus, Scot W.

Volltext

Synthesis and Evaluation of a Triplex-Forming Oligonucleotide−Pyrrolobenzodiazepine Conjugate von Zhilina, Zhanna V, Ziemba, Amy J, Trent, John O, Reed, Michael W, Gorn, Vladimir, Zhou, Qun, Duan, Wenhu, Hurley, Laurence, Ebbinghaus, Scot W

Volltext

Triplex formation by morpholino oligodeoxyribonucleotides in the HER-2/neu promoter requires the pyrimidine motif von Basye, J, Trent, J O, Gao, D, Ebbinghaus, S W

Volltext

A Bis-Alkylating Triplex Forming Oligonucleotide Inhibits Intracellular Reporter Gene Expression and Prevents Triplex Unwinding Due to Helicase Activity von Ziemba, Amy J, Reed, Michael W, Raney, Kevin D, Byrd, Alicia B, Ebbinghaus, Scot W

Volltext

Inhibition of Transcription Elongation in the HER-2/neu Coding Sequence by Triplex-Directed Covalent Modification of the Template Strand von Ebbinghaus, Scot W, Fortinberry, Henry, Gamper, Howard B

Volltext